RecruitingPhase 2NCT07024693

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty

Sponsor

Design Therapeutics, Inc.

Enrollment

28 participants

Start Date

Jul 30, 2025

Study Type

INTERVENTIONAL

Conditions

Fuchs' Endothelial Corneal Dystrophy Fuchs

Summary

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DT-168 for people with fuchs and fuchs' endothelial corneal dystrophy. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 30 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDT-168

Active

Locations(2)

DTX-168-201 Study Site

Indianapolis, Indiana, United States

DTX-168-201 Study Site

Grand Rapids, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07024693

Related Trials

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT044402801 location

Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)

NCT073738211 location